Part 1: When to test

Share :
Published: 23 Jul 2021
Views: 3745
PARP inhibition in the treatment of prostate cancer

This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.

Both EAU and NCCN guidelines suggest germline testing in men with metastatic prostate cancer.

They also suggest considering testing in men under 60 years old with multiple family members diagnosed with prostate cancer.

This video gives guidelines on when someone should be tested for prostate cancer and what options are available.

To learn about who to test for prostate cancer click here.

To learn about how to test for prostate cancer click here.

To learn about metastatic prostate cancer and HRR defects click here.

To learn about BRCA 1-2 mutations and prostate cancer click here.

To watch an expert panel discussion on the role of testing in prostate cancer treatment click here.

To watch a discussion on the latest on PARPi and other treatments for mCRPC click here.

This programme has been supported by an unrestricted educational grant from AstraZeneca.